CHICAGO, June 7, 2024 /PRNewswire/ -- The autologous stem cell and non-stem cell therapies market is set to grow significantly, with estimates suggesting a rise to $22.2 billion by 2029 from $5.5 billion in 2024, indicating a CAGR of 32.3%. This growth is fueled by regulatory approvals for innovative therapies like autologous CAR T-cell and Tumor Infiltrating Lymphocyte (TIL) therapies, along with increased investments in research and development. Key players such as Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, Novartis, JW Therapeutics, and Iovance Biotherapeutics are leading the charge, addressing the rising demand for effective cancer treatments. Hospitals and clinics play a crucial role in facilitating efficient cell collection and treatment delivery. The North American region is expected to see the highest growth, driven by research investments, healthcare infrastructure improvements, and the adoption of autologous stem cell and non-stem cell-based therapies for cancer and chronic diseases. Overall, the market shows promising prospects driven by technological advancements and a focus on personalized treatment.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=837
Browse in-depth TOC on "Autologous Stem Cell & Non-stem Cell Therapies Market"
326 - Tables
49 - Figures
309 - Pages
In 2023, autologous non-stem cell therapies held the largest share of the type segment in the autologous stem cell & non-stem cell therapies market.
Autologous non-stem cell therapies are a significant sub-segment within the autologous stem cell & non-stem cell therapies market. This sub-segment commanded the largest market share in the autologous stem cell & non-stem cell therapies market in 2023. This dominance can be attributed to the increasing approvals for CAR T cell therapies and the rising global incidence of cancer cases, driving demand for effective treatment options like autologous CAR T cell therapies.
Cancer Indications Dominate the Market
In 2023, cancer indications commanded the largest share among indication segments in the autologous stem cell & non-stem cell therapies market. This dominance is attributed to the growing global burden of cancer cases, propelling demand for cancer therapeutics. Ongoing research and development efforts are contributing to the creation of more effective treatments, particularly for various types of solid tumors.
Hospitals and Clinics Lead in End-User Segment
Hospitals and clinics emerged as the primary end-user segment in the autologous stem cell & non-stem cell therapies market in 2023. This predominance is driven by the increasing regulatory approvals for autologous non-stem cell therapies for cancer and chronic diseases. With the rising prevalence of cancer worldwide, hospitals provide essential infrastructure for apheresis, a critical process in cell collection for autologous cell therapies. Collaboration between biopharmaceutical firms and hospitals streamlines this process, ensuring prompt and efficient treatment delivery to patients.
North America Anticipated to Lead in Growth
North America is expected to witness the highest compound annual growth rate (CAGR) in the autologous stem cell & non-stem cell therapies market. This growth is fueled by increased investments in research, the expansion of the healthcare sector, rising cancer prevalence, and the growing adoption of autologous stem cell and non-stem cell-based therapies for cancer and chronic diseases.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=837
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side - 30%
- By Designation: C Level Executives- 55%, CXOs, and Director level - 20%, and Others- 25%
- By Region: North America -50%, Europe - 20%, Asia-Pacific -20%, RoW -10%
Recent Developments in the Industry
- In April 2024, Bristol-Myers Squibb Company (US) inked a global capacity reservation and supply agreement with Cellares (US) to manufacture CAR T-cell therapies utilizing Cellares's advanced automated manufacturing platform known as Cell Shuttle.
- In October 2023, Kite Pharma, a subsidiary of Gilead Sciences, Inc. (US), partnered with Epicrispr Biotechnologies, Inc. (US) to adopt regulatory technology for the advancement of next-generation cancer cell therapies, specifically focusing on enhancing CAR T cell functionality.
Latest Insights from the Autologous Stem Cell & Non-Stem Cell Therapies Market Report
The most recent iteration of the report marks a shift in the base year to 2023 and extends the forecast period from 2024 to 2029. Updated volume data for key autologous non-stem cell-based drugs is provided for the years 2022 to 2029, alongside refreshed financials and product portfolios of market players, with graphical representation of financial information from 2021-2023 for each listed company. Market developments of profiled players are covered from January 2021 to April 2024, with an encompassing overview including market dynamics, pipeline analysis of Phase III molecules, technological analysis, case study analysis, and investment and funding activities. The number of profiled companies has increased from 16 to 28, accompanied by an updated company evaluation matrix for both autologous stem cell & non-stem cell-based therapeutic product players and startups/SMEs. Furthermore, region, type, indication, source, and end-user footprints for key players are included, along with competitive benchmarking for startups/SMEs in the competitive landscape chapter. Newly integrated features into the competitive landscape chapter include brand/product comparative analysis, vendor valuation, and financial metrics.
For more information, inquire now! Inquire Now
Related Reports:
Stem Cell Therapy Market - Global Forecasts to 2028
Biologics Safety Testing Market - Global Forecasts to 2029
Nerve Repair & Regeneration Market - Global Forecasts to 2027
Regenerative Medicine Market - Global Forecasts to 2028
Cell Expansion Market - Global Forecasts to 2029
Get access to the latest updates on Autologous Stem Cell & Non-stem Cell Therapies Companies and Autologous Stem Cell & Non-stem Cell Therapies Industry
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/by-2029--the-autologous-stem-cell--non-stem-cell-therapies-market-is-forecasted-to-attain-a-value-of-22-2-billion--marketsandmarkets-302167044.html
